Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.50
-0.73 (-4.79%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Janux Therapeutics Revenue
In the year 2025, Janux Therapeutics had annual revenue of $10.00M, down -5.55%.
Revenue (ttm)
$10.00M
Revenue Growth
-5.55%
P/S Ratio
88.21
Revenue / Employee
$91,743
Employees
109
Market Cap
882.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Maravai LifeSciences Holdings | 185.74M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| Theravance Biopharma | 107.46M |
| MeiraGTx Holdings | 81.39M |
| CytomX Therapeutics | 76.20M |
JANX News
- 1 day ago - Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - Business Wire
- 12 days ago - Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 - Business Wire
- 27 days ago - Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire
- 2 months ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
- 3 months ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 3 months ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 3 months ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters